• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

NIHR Oxford Health Biomedical Research Centre

Improving brain health: the future in mind

MENUMENU
  • About
    • About
    • Our People
    • Timeline of our key achievements since 2017
    • Core facilities
    • Management and partners
    • Work with us
    • Contact
  • Departments
    • NIHR Oxford Cognitive Health Clinical Research Facility
    • Brain Health Centre
    • Oxford Precision Psychiatry Lab (OxPPL)
    • Oxford Dementia and Ageing Research (OxDARE)
    • Treatment Resistant Depression Clinic
    • Experimental Medicine and Industry Partnership (EMIP)
  • Research Themes
    • Overview of Research Themes
    • Adult Mental Health
    • Older Adults and Dementia
    • Precision Psychological Therapies
    • Clinical Research Infrastructure and Experimental Medicine
    • Informatics and Digital Health
    • Neuroimaging and Cognitive Neuroscience
    • Patient and Public Involvement
    • Training theme
    • Theme Leads
  • COVID-19 Research
    • Overview
    • News
    • COVID-19 & clinical management of mental health issues
  • News & Events
    • News
    • Blog
    • Training & Events
    • Psychiatry department seminars
  • Training Hub
  • Patients & Public
    • About Patient and Public Involvement
    • Shape our research
    • Take part in our research
    • Resources for researchers
    • Resources for the public
    • Patient and Public Involvement Strategy
    • Young people’s involvement
You are here: Home / Departments / Welcome to the Oxford Precision Psychiatry Lab (OxPPL) / Systematic reviews and meta-analysis

Oxford Precision Psychiatry Lab

Systematic reviews and meta-analysis


Precision medicine in psychiatry – a focus on treatment prediction in depression: a meta-review

Summary

This is a meta-review to identify individual predictors of treatment effect of pharmacological, psychological, electroconvulsive and neuromodulatory treatments in unipolar depression. We also aim to identify, catalogue and evaluate clinical prediction models of treatment effect with a specific focus in unipolar depression, complemented by a non-systematic exploration of clinical prediction models used in other fields.

Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Orestis Efthimiou, Institute of Social and Preventive Medicine, Bern, Switzerland
George Gillet, Department of Psychiatry, University of Oxford, Oxford, UK
Anneka Tomlinson, Department of Psychiatry, University of Oxford, Oxford, UK

Protocol

Gillet et al., Precision medicine in psychiatry – a focus on treatment prediction in depression: a meta review

Prospero

https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=141425


Sleep deprivation as a treatment for major depressive episodes: a systematic review and meta-analysis

Summary

To assess the efficacy, acceptability and tolerability of sleep deprivation in comparison to any other intervention for the acute and long-term treatment of major depressive episodes in unipolar or bipolar affective disorders.

Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Franco De Crescenzo, Department of Psychiatry, University of Oxford, Oxford, UK
John Geddes, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Simon Kyle, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
Pamina Mitter, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Anneka Tomlinson, Department of Psychiatry, University of Oxford, Oxford, UK

Protocol

Mitter et al., Sleep deprivation as a treatment for major depressive episodes: a systematic review and meta-analysis

Prospero

Under review


Informing National Health Service patients about participation in clinical research: A comparison of opt-in and opt-out approaches across the United Kingdom

Summary

Recruitment to clinical research in the National Health Service remains challenging. One barrier is accessing patients to discuss research participation. Two general approaches are used in the United Kingdom to facilitate this: an ‘opt-in’ approach (when clinicians communicate research opportunities to patients) and an ‘opt-out’ approach (all patients have the right to be informed of relevant research opportunities). No evidence-based data are available, however, to inform the decision about which approach is preferable. This study aimed to collect information from ‘opt-in’ and ‘opt-out’ Trusts and identify which of the two approaches is optimal for ensuring National Health Service patients are given opportunities to discuss research participation.

Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Nick Broughton, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Roger Ede, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
John R Geddes, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Mark Hancock, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Catherine Henshall, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK; Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK
Catherine Kernot, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Lorcan O’Neill, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Jennifer Potts, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Mark Underwood, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Sophie Walker, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK


Ketamine and other glutamate receptor modulators for depression in adults: Cochrane Review

Summary
  • An update to Caddy et al. (2015), with the following aims:
    • To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with unipolar major depressive disorder.
    • To review the acceptability of ketamine and other glutamate receptor modulators in people with unipolar major depressive disorder.
    • To investigate the adverse effects of ketamine and other glutamate receptor modulators in people with unipolar major depressive disorder.
Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Annabelle Barnes, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Phil Cowen, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Rebecca Dean, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Keith Hawton, Centre for Suicide Research, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Sarah Hollingsworth, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Claudia Hurducas, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Tahnee Marquardt, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Rupert McShane, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
Rebecca Smith, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Stella Spyridi, Department for Rehabilitation Sciences, Cyprus University of Technology
Erick Turner, Portland Veterans Affairs Medical Center, Portland, USA


Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults: Cochrane Review

Summary
  • An update to McCloud et al. (2015), with the following aims:
    • To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder.
    • To review the acceptability of ketamine and other glutamate receptor modulators in people with depression and bipolar disorder.
    • To investigate the adverse effects of ketamine and other glutamate receptor modulators in people with depression and bipolar disorder.
Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Annabelle Barnes, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Phil Cowen, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Rebecca Dean, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Keith Hawton, Centre for Suicide Research, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Sarah Hollingsworth, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Claudia Hurducas, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Tahnee Marquardt, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Rebecca Smith, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Stella Spyridi, Department for Rehabilitation Sciences, Cyprus University of Technology

Primary Sidebar

Oxford Precision Psychiatry Lab

  • Welcome
  • COVID-19 & clinical management of mental health issues
    • Media – articles and videos
  • International projects
  • Systematic reviews and meta-analysis
  • Patient Involvement and Ethics
  • Publications
  • OxPPL Team
  • OxPPL Events

Tweets by Oxford Precision Psychiatry Lab

Tweets by OxfordPPL
Follow @OxfordPPL

Footer

Follow us

  • Twitter
  • YouTube

Improving brain health: the future in mind

The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford. We are part of the Oxford Academic Health Science Centre.

Oxford Academic Health Science Centre
  • Sitemap
  • Accessibility
  • Disclaimer
  • Cookies
  • Contact

© 2022 NIHR Oxford Health Biomedical Research Centre · Log in

Cookies

This site uses cookies: See our privacy policy